Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Life Sciences Firm Gains Approval to Sell Non-Antibiotic Livestock Feed Additive in Brazil
News Update

Share on Stocktwits


Avivagen reported it received approval for use of OxC-beta™ Livestock in Brazil and it has signed an agreement with a São Paulo company for distribution.

In a news release, Avivagen Inc. (VIV:TSX.V; VIVXF:OTCQB), which develops and commercializes immune-system improving products for livestock, companion animal and human applications, announced "it has received approval from the Ministry of Agriculture-Feed Additives Division for the immediate use of OxC-beta™ Livestock in poultry, swine and cattle (beef and dairy) in Brazil."

The firm advised that after gaining regulatory approval, it entered into a distribution agreement with a São Paulo import/export company, Look Chemicals Importacao E Exportacao LTDA, for use of OxC-betaTM Livestock in poultry and swine.

The company's CEO Kym Anthony commented, "We are very excited to secure approval for the use of OxC-beta™ Livestock in Brazil, one of the world's largest livestock feed markets and an important exporter to many key regions worldwide...With a local distribution agreement already in place with well-regarded Look Chemicals we expect to see quick adoption of OxC-betaTM Livestock in the South American market, with Brazil becoming an important part of Avivagen's continued growth worldwide."

The firm explained that Brazil is the world's third largest livestock feed production market and a key exporter to regions including Europe that have enacted regulations banning the use of antibiotics in livestock feed. The company indicated that OxC-beta™ Livestock is now approved for use in nine markets worldwide including Australia, Brazil, Malaysia, Mexico, New Zealand, the Philippines, Taiwan, Thailand and the U.S.

Avivagen develops and commercializes products for livestock, companion animal and human applications. The company stated its OxC-beta™ technology is derived from its discoveries surrounding β-carotene and other carotenoids, which it advised are the compounds that cause many fruits and vegetables to exhibit bright colors.


1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Want to read more about Agriculture investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe